Lipidomics is providing new insight into the metabolic syndrome and its sequelae

Abstract

The global view of lipid metabolism offered by lipidomics is accelerating our understanding of disease processes and identifying new avenues of research into metabolic syndrome and its sequelae. The ongoing identification and validation of lipid biomarkers will likely see their introduction into clinical practice for improved quantification of disease risk, earlier identification of disease and improved patient management in the near future.

The rare allele of DGKZ SNP rs10838599 is associated with variability in HDL-cholesterol levels among severely obese patients

“…To our knowledge, this study is the first to report an association of DGKZ gene variations and cardiometabolic risk factors in severely obese patients. Rs10838599 wild-type allele was associated with decreased plasma HDL-C levels, a lipid disturbance associated with an alteration of free fatty acid metabolism [16,31]. Low plasma HDL-C level is a criterion of MetS and an important indicator of increased cardiovascular risk [1,32].…”

Flow Field-Flow Fractionation with Mass Spectrometry for Top-Down and Bottom-Up Lipidomics

“…Because lipids are engaged in various cellular processes such as cell signaling, energy storage, and cell structure composition, they can be regarded as potential disease markers, as their abnormal metabolism is related with the onset of many illnesses [1][2][3]. Among the different classes of lipids, the most abundant are the phospholipids (PLs), which are amphipathic structures consisting of non-polar fatty acyl chains connected to a polar phosphate group by a glycerol backbone.…”

Plasma Lipidomic Profile Signature of Hypertension in Mexican American Families

“…[6][7][8][9] This research may help explain the variable expression of the metabolic syndrome features between individuals and groups with access to excess. If causal relationships are defined, this third millennial science may inform and accelerate novel therapeutic approaches to efficiently prevent and manage the metabolic syndrome.…”

“…6 These questions can be and are being addressed in studies of genetically engineered cells and small animals. 7 Insight from these studies is informing the development of traditional and novel therapeutics to alter the abundance or activity of enzymes/proteins underlying variations in the lipidomic profile and related phenotypic expression, including blood pressure, glucose metabolism, insulin dynamics and action, and organ-specific lipid storage.…”

“…6,7 In their insightful review, Chavez and Summers 7 posited that excess dietary calories and lipids (environmental) were a major factor in the generation of lipid species (eg, ceramide, diglycerides, and other lipid species that are plausibly linked to diabetes mellitus, hypertension, and nonalcoholic fatty liver disease). They quoted the 17th century English writer Robert Burton, "Gluttony is the source of all our infirmities, and the fountain of all our diseases.…”